Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study


Autoři: Hannah Lawrence aff001;  Harry Pick aff001;  Vadsala Baskaran aff001;  Priya Daniel aff004;  Chamira Rodrigo aff001;  Deborah Ashton aff001;  Rochelle C. Edwards-Pritchard aff005;  Carmen Sheppard aff006;  Seyi D. Eletu aff006;  David Litt aff006;  Norman K. Fry aff006;  Samuel Rose aff006;  Caroline Trotter aff008;  Tricia M. McKeever aff002;  Wei Shen Lim aff001
Působiště autorů: Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom aff001;  Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom aff002;  NIHR Nottingham Biomedical Research Centre, Queen’s Medical Centre, Nottingham, United Kingdom aff003;  Department of Respiratory Medicine, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom aff004;  Division of Respiratory Medicine, University of Nottingham, Nottingham, United Kingdom aff005;  Respiratory and Vaccine Preventable Bacteria Reference Unit, Public Health England–National Infection Service, Colindale, London, United Kingdom aff006;  Immunisation and Countermeasures Division, Public Health England Colindale–National Infection Service, London, United Kingdom aff007;  Disease Dynamic Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom aff008
Vyšlo v časopise: Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. PLoS Med 17(10): e32767. doi:10.1371/journal.pmed.1003326
Kategorie: Research Article
doi: 10.1371/journal.pmed.1003326

Souhrn

Background

Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available in the United Kingdom to adults aged 65 years or older and those in defined clinical risk groups. We evaluated the vaccine effectiveness (VE) of PPV23 against vaccine-type pneumococcal pneumonia in a cohort of adults hospitalised with community-acquired pneumonia (CAP).

Methods and findings

Using a case-control test-negative design, a secondary analysis of data was conducted from a prospective cohort study of adults (aged ≥16 years) with CAP hospitalised at 2 university teaching hospitals in Nottingham, England, from September 2013 to August 2018. The exposure of interest was PPV23 vaccination at any time point prior to the index admission. A case was defined as PPV23 serotype-specific pneumococcal pneumonia and a control as non-PPV23 serotype pneumococcal pneumonia or nonpneumococcal pneumonia. Pneumococcal serotypes were identified from urine samples using a multiplex immunoassay or from positive blood cultures. Multivariable logistic regression was used to derive adjusted odds of case status between vaccinated and unvaccinated individuals; VE estimates were calculated as (1 − odds ratio) × 100%. Of 2,357 patients, there were 717 PPV23 cases (48% vaccinated) and 1,640 controls (54.5% vaccinated). The adjusted VE (aVE) estimate against PPV23 serotype disease was 24% (95% CI 5%–40%, p = 0.02). Estimates were similar in analyses restricted to vaccine-eligible patients (n = 1,768, aVE 23%, 95% CI 1%–40%) and patients aged ≥65 years (n = 1,407, aVE 20%, 95% CI −5% to 40%), but not in patients aged ≥75 years (n = 905, aVE 5%, 95% CI −37% to 35%). The aVE estimate in relation to PPV23/non-13-valent pneumococcal conjugate vaccine (PCV13) serotype pneumonia (n = 417 cases, 43.7% vaccinated) was 29% (95% CI 6%–46%). Key limitations of this study are that, due to high vaccination rates, there was a lack of power to reject the null hypothesis of no vaccine effect, and that the study was not large enough to allow robust subgroup analysis in the older age groups.

Conclusions

In the setting of an established national childhood PCV13 vaccination programme, PPV23 vaccination of clinical at-risk patient groups and adults aged ≥65 years provided moderate long-term protection against hospitalisation with PPV23 serotype pneumonia. These findings suggest that PPV23 vaccination may continue to have an important role in adult pneumococcal vaccine policy, including the possibility of revaccination of older adults.

Klíčová slova:

Adults – Conjugate vaccines – Chronic obstructive pulmonary disease – Influenza – Pneumonia – Polysaccharides – Vaccination and immunization – Vaccines


Zdroje

1. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8(4):e60273. Epub 2013/04/09. doi: 10.1371/journal.pone.0060273 23565216; PubMed Central PMCID: PMC3615022.

2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9. Epub 2010/08/24. doi: 10.1136/thx.2009.129502 20729232.

3. Public Health England P. Immunisation against infectious disease—The Green Book. Chapter 25: Pneumococcal 2018 [cited 2019 Dec 1]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/674074/GB_Chapter_25_Pneumococcal_V7_0.pdf.

4. Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, et al. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom. The Journal of infectious diseases. 2019. doi: 10.1093/infdis/jiz178 31004136

5. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. The Lancet Infectious diseases. 2018;18(4):441–51. Epub 2018/02/06. doi: 10.1016/S1473-3099(18)30052-5 29395999.

6. Pick H, Daniel P, Rodrigo C, Bewick T, Ashton D, Lawrence H, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. Thorax. 2019. Epub 2019/10/09. doi: 10.1136/thoraxjnl-2019-213725 31594801.

7. Public Health England P. Pneumococcal Polysacchardie Vaccine (PPV) coverage report, England, April 2017 to March 2018. 2018 27 July 2018. Report No.: Number 27.

8. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. The Cochrane database of systematic reviews. 2013;(1):Cd000422. Epub 2013/02/27. doi: 10.1002/14651858.CD000422.pub3 23440780.

9. Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine. 2018;6:42–50. Epub 2019/06/14. doi: 10.1016/j.eclinm.2018.12.007 31193709; PubMed Central PMCID: PMC6537583.

10. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Cmaj. 2009;180(1):48–58. Epub 2009/01/07. doi: 10.1503/cmaj.080734 19124790; PubMed Central PMCID: PMC2612051.

11. Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. BMC medicine. 2018;16(1):13. Epub 2018/02/09. doi: 10.1186/s12916-018-1004-z 29415741; PubMed Central PMCID: PMC5804014.

12. Rodrigo C, Bewick T, Sheppard C, Greenwood S, McKeever TM, Trotter CL, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. The European respiratory journal. 2015;45(6):1632–41. Epub 2015/03/21. doi: 10.1183/09031936.00183614 25792633.

13. Boddington NL, Warburton F, Zhao H, Andrews N, Ellis J, Donati M, et al. Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015–2016 influenza season—a test-negative case-control study. Epidemiology and infection. 2019;147:e201-e. doi: 10.1017/S0950268819000876 31364557.

14. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. The Lancet Infectious diseases. 2017;17(3):313–21. Epub 2017/01/28. doi: 10.1016/S1473-3099(17)30049-X 28126327.

15. Eletu SD, Sheppard CL, Thomas E, Smith K, Daniel P, Litt DJ, et al. Development of an Extended-Specificity Multiplex Immunoassay for Detection of Streptococcus pneumoniae Serotype-Specific Antigen in Urine by Use of Human Monoclonal Antibodies. Clin Vaccine Immunol. 2017;24(12). Epub 2017/10/06. doi: 10.1128/CVI.00262-17 28978509; PubMed Central PMCID: PMC5717182.

16. Eletu SD, Sheppard CL, Rose S, Smith K, Andrews N, Lim WS, et al. Re-validation and update of an extended-specificity multiplex assay for detection of Streptococcus pneumoniae capsular serotype/serogroup-specific antigen and cell-wall polysaccharide in urine specimens. Access Microbiology. 2020. https://doi.org/10.1099/acmi.0.000094.

17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982;5(6):649–55. Epub 1982/12/01. 7165009.

18. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology (Cambridge, Mass). 2011;22(5):745. Epub 2011/08/04. doi: 10.1097/EDE.0b013e318225c2be 21811114.

19. Sintes X, Nebot M, Izquierdo C, Ruiz L, DomÍNguez A, Bayas JM, et al. Factors associated with pneumococcal and influenza vaccination in hospitalized people aged ⩾65 years. Epidemiology and infection. 2011;139(5):666–73. Epub 2010/08/09. doi: 10.1017/S0950268810001846 20696084

20. StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC. 2019.

21. Kim JH, Chun BC, Song JY, Kim HY, Bae IG, Kim DM, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study. Vaccine. 2019;37(21):2797–804. Epub 2019/04/22. doi: 10.1016/j.vaccine.2019.04.017 31005428.

22. Haessler S, Lindenauer PK, Zilberberg MD, Imrey PB, Yu PC, Higgins T, et al. Blood cultures versus respiratory cultures: Two different views of pneumonia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019. Epub 2019/10/31. doi: 10.1093/cid/ciz1049 31665249.

23. McLaughlin JM, Jiang Q, Gessner BD, Swerdlow DL, Sings HL, Isturiz RE, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine. 2019;37(43):6310–6. Epub 2019/09/17. doi: 10.1016/j.vaccine.2019.08.059 31522807.

24. Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine. 2019;37(8):1021–9. doi: 10.1016/j.vaccine.2019.01.014 30685252

25. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. The Journal of infectious diseases. 1997;176(4):1100–4. Epub 1997/10/23. 9333177. doi: 10.1086/516521 9333177

26. Vaccines against influenza WHO position paper—November 2012. Releve epidemiologique hebdomadaire. 2012;87(47):461–76. Epub 2012/12/06. 23210147.

27. Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged > = 50 years with community-acquired pneumonia. Journal of Infectious Diseases. 2013;208(11):1813–20. doi: 10.1093/infdis/jit506 24092845.

28. Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, et al. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine. 2019;37(25):3352–61. Epub 2019/05/11. doi: 10.1016/j.vaccine.2019.04.087 31072732.

29. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. The Lancet Infectious diseases. 2005;5(2):83–93. Epub 2005/02/01. doi: 10.1016/S1473-3099(05)01280-6 15680778.

30. Romney MG, Hull MW, Gustafson R, Sandhu J, Champagne S, Wong T, et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008;47(6):768–74. Epub 2008/08/12. doi: 10.1086/591128 18690803.

31. Pimenta F, Gertz RE Jr., Park SH, Kim E, Moura I, Milucky J, et al. Streptococcus infantis, Streptococcus mitis, and Streptococcus oralis Strains With Highly Similar cps5 Loci and Antigenic Relatedness to Serotype 5 Pneumococci. Frontiers in microbiology. 2018;9:3199. Epub 2019/01/24. doi: 10.3389/fmicb.2018.03199 30671034; PubMed Central PMCID: PMC6332807.

32. Jackson ML. Use of self-reported vaccination status can bias vaccine effectiveness estimates from test-negative studies. Vaccine: X. 2019;1:100003. https://doi.org/10.1016/j.jvacx.2018.100003.

33. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. Seminars in Immunology. 2018;40:83–94. doi: 10.1016/j.smim.2018.10.010 30501873

34. Daniel P, Rodrigo C, Bewick T, Sheppard C, Greenwood S, McKeever TM, et al. Increased incidence of adult pneumococcal pneumonia during school holiday periods. ERJ open research. 2017;3(1). Epub 2017/03/23. doi: 10.1183/23120541.00100–2016 28326311; PubMed Central PMCID: PMC5349095 openres.ersjournals.com.

35. Rodrigo C, Bewick T, Sheppard C, Greenwood S, Macgregor V, Trotter C, et al. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status. Thorax. 2014;69(2):168–73. Epub 2013/09/21. doi: 10.1136/thoraxjnl-2013-203987 24048505.

36. British Thoracic Society B, Lawrence H, Lim WS. National Audit Report: Adult Community Acquired Pneumonia Audit 2018–2019. Online: 2019.

37. Robert Koch Institut S. Recommentations of the Standing Committee on Vacciantion (STIKO) at the Robert Koch Institue—2017/2018. 2017:Page 371.

38. Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E, et al. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS ONE. 2018;13(2):e0192640. Epub 2018/02/10. doi: 10.1371/journal.pone.0192640 29425249; PubMed Central PMCID: PMC5806887.

39. Caya CA, Boikos C, Desai S, Quach C. Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review. Vaccine. 2015;33(11):1302–12. Epub 2015/02/11. doi: 10.1016/j.vaccine.2015.01.060 25660650.

40. Takashima M, Lambert SB, Paynter S, Ware RS. Relative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and Torres Strait Islander people, Australia. Vaccine. 2019;37(12):1638–41. Epub 2019/02/21. doi: 10.1016/j.vaccine.2019.01.085 30782489.


Článek vyšel v časopise

PLOS Medicine


2020 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se